HOME > ARCHIVE

ARCHIVE

Requirements for FY2005 GE Drug Listing Announced

March 28, 2005
MONITOR

March 28, 2005
Receipt of Applications for DMF Started

March 28, 2005
DIAGNOSTIC NEWS IN BRIEF

March 28, 2005
Revised GL on Use of Gefitinib Reviewed

March 28, 2005
MEET THE LEADERS (41)

March 28, 2005
REGULATORY NEWS IN BRIEF

March 28, 2005
Overseas Group Companies under Astellas Announced

March 28, 2005
GL for Package Inserts for Patients in Preparation

March 28, 2005
Monitor

March 21, 2005
Early Data Show Significant Antiplatelet Action for Prasugrel: Sankyo

March 21, 2005
Novo Nordisk Aims at Yearly Growth of 10%: Mr Eilersen

March 21, 2005
New Study Results on Oral CCR5 Receptor Antagonist Presented: Ono

March 21, 2005
BULLETIN

March 21, 2005
Seikagaku to Focus on Joint Diseases, Glycosaminoglycans in R&D

March 21, 2005
Norvasc Remains No.1 in 4th Qtr: IMS Survey

March 21, 2005
RESEARCH & DEVELOPMENT NEWS IN BRIEF

March 21, 2005
Banyu Aiming for Annual Sales of \350 Bil. at Early Date: Mr Hirate

March 21, 2005
PRESS SEMINAR

March 21, 2005
Meiji Seika to Enlist Help of MSs in Marketing Activities

March 21, 2005

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…